A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)
CODICE STUDIO
NCT05519085
TIPOLOGIA
Ricaduti
NOME SPONSOR
Bristol-Myers Squibb
DESCRIZIONE
<h2>Trattamento</h2>
Experimental 480Vd (CC-92480, bortezomib and dexamethasone):
CC-92480
<ul>
<li>Specified dose on specified days</li>
<li>Other Names:
<ul>
<li>BMS-986348</li>
<li>Mezigdomide</li>
</ul>
</li>
</ul>
Bortezomib
<ul>
<li>Specified dose on specified days</li>
<li>Other Names:
<ul>
<li>Velcade</li>
<li>BTZ</li>
</ul>
</li>
</ul>
Dexamethasone
<ul>
<li>Specified dose on specified days</li>
<li>Other Names:
<ul>
<li>Decadron</li>
<li>Dex</li>
</ul>
</li>
</ul>
Experimental: PVd (pomalidomide, bortezomib and dexamethasone):
Pomalidomide
<ul>
<li>Specified dose on specified days</li>
<li>Other Names:
<ul>
<li>Pomalyst</li>
<li>Imnovid</li>
<li>Pom</li>
</ul>
</li>
</ul>
Bortezomib
<ul>
<li>Specified dose on specified days</li>
<li>Other Names:
<ul>
<li>Velcade</li>
<li>BTZ</li>
</ul>
</li>
</ul>
Dexamethasone
<ul>
<li>Specified dose on specified days</li>
<li>Other Names:
<ul>
<li>Decadron</li>
<li>Dex</li>
</ul>
</li>
</ul>
FARMACI UTILIZZATI